Humoral immune response to α-methylacyl-CoA racemase and prostate cancer

Journal of the National Cancer Institute

Volumn 96, Issue 11, 2004, Pages 834-843

  Sreekumar, Arun ^a   Laxman, Bharathi ^a   Rhodes, Daniel R ^a   Bhagavathula, Srilakshmi ^a   Harwood, Jason ^a   Giacherio, Donald ^a   Ghosh, Debashis ^a   Sanda, Martin G ^a   Rubin, Mark A ^b   Chinnaiyan, Arul M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ACYL COENZYME A; BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; RACEMASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ALPHA-METHYLACYL-COA RACEMASE; AUTOANTIBODY; ISOMERASE; TUMOR MARKER;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOBLOTTING; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN MICROARRAY; ROC CURVE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; GENE EXPRESSION REGULATION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; RACEMASES AND EPIMERASES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 2942612648     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh145     Document Type: Article

References (31)

1. von Knobloch R, Konrad L, Barth PJ, Brandt H, Wille S, Heidenreich A, et al. Genetic pathways and new progression markers for prostate cancer suggested by microsatellite allelotyping. Clin Cancer Res 2004;10:1064-73.
2. Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer - part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999; 91:1033-9.
3. Maattanen L, Auvinen A, Stenman UH, Rannikko S, Tammela T, Aro J, et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999;79:1210-4.
4. Schroder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998;90:1817-23.
5. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994;331:996-1004.
6. Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995;274:1445-9.
7. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003;349:335-42.
8. Ferdinandusse S, Denis S, Lodewijk I, Dacremont G, Waterham HR, Wanders RJ. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 2000;41:1890-6.
9. Kotti TJ, Savolainen K, Helander HM, Yagi A, Novikov DK, Kalkkinen N, et al. In mouse alpha-methylacyl-CoA racemase, the same gene product is simultaneously located in mitochondria and peroxisomes. I Biol Chem 2000;275:20887-95.
10. Schmitz W, Albers C, Fingerhut R, Conzelmann E. Purification and characterization of an alpha-methylacyl-CoA racemase from human liver. Eur J Biochem 1995;231:815-22.
11. Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000;60:1677-82.
12. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, et al. Gene expression analysis of prostate cancers. Mol Carcinog 2002;33:25-35.
13. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
14. Welsh JB, Sapinoso LM, So AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.
15. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002;62: 4427-33.
16. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001;25:1397-404.
17. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-70.
18. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002;62:2220-6.
19. Zheng SL, Chang BL, Faith DA, Johnson JR, Isaacs SD, Hawkins GA, et al. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk. Cancer Res 2002;62:6485-8.
20. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
21. McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 2000;164:1825-9.
22. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003;21:57-63.
23. Nilsson BO, Carlsson L, Larsson A, Ronquist G. Autoantibodies to prostasomes as new markers for prostate cancer. Ups J Med Sci 2001; 106:43-9.
24. Gleason D. Classification of prostate carcinomas. Cancer Chemother Rep 1966;50:125-8.
25. Gleason D, The Veterans Administration Cooperative Urological Research Group. Histologic grading and clinical staging of prostate carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia (PA): Lea & Febiger; 1977. p. 171-98.
26. Sreekumar A, Nyati MK, Varambally S, Barrette TR, Ghosh D, Lawrence TS, et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res 2001;61:7585-93.
27. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61:4683-8.
28. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002; 26:926-31.
29. Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, et al. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 2003;34:792-6.
30. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383-91.
31. Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am 1997;24:353-65.